Current Report Filing (8-k)
April 08 2020 - 4:30PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Current Report
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event
reported): April 7, 2020
ANAVEX LIFE SCIENCES CORP.
(Exact name of registrant as specified in its charter)
Nevada
|
|
001-37606
|
|
98-0608404
|
(State or other jurisdiction
|
|
(Commission
|
|
(IRS Employer
|
of incorporation)
|
|
File Number)
|
|
Identification No.)
|
51 West 52nd Street, 7th Floor, New York,
NY USA 10019
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including
area code 1-844-689-3939
Not Applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form
8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
(see General Instruction A.2. below):
☐
Written communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17
CFR 240.14a -12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
Act (17 CFR 240.14d -2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
Act (17 CFR 240.13e -4(c))
Securities registered pursuant to Section 12(b)
of the Act:
Title of each class
|
|
Trading symbol(s)
|
|
Name of each exchange on which
registered
|
Common Stock, $0.001 par value
|
|
AVXL
|
|
The Nasdaq Stock Market LLC
|
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the
Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.07.
|
Submission of Matters to a Vote of Security Holders.
|
On April 7, 2020, Anavex Life Sciences
Corp., a Nevada corporation (the “Company”), held a special meeting of stockholders (the “Meeting”)
as prescribed in the Proxy Statement filed by the Company with the Securities and Exchange Commission on February 20, 2020. At
the Meeting, two proposals were submitted for a vote of the Company’s stockholders and the related results are as follows:
Proposal No. 1: The election
of Christopher Missling, Ph.D., Claus van der Velden, Ph.D., Athanasios Skarpelos, Elliot Favus, M.D., Steffen Thomas, Ph.D., and
Peter Donhauser, D.O. for terms until the next annual meeting of stockholders or until each such director’s successor shall
have been duly elected and qualified. The stockholders elected each of the six directors by the following votes:
Director
|
Votes For
|
Votes Withheld
|
Broker Non-Votes
|
Christopher Missling, Ph.D.
|
21,276,670
|
228,009
|
23,719,166
|
Claus van der Velden, Ph.D.
|
18,628,173
|
2,876,506
|
23,719,166
|
Athanasios Skarpelos
|
20,380,573
|
1,124,106
|
23,719,166
|
Elliot Favus, M.D.
|
21,335,208
|
169,471
|
23,719,166
|
Steffen Thomas, Ph.D.
|
19,527,259
|
1,977,420
|
23,719,166
|
Peter Donhauser, D.O.
|
19,518,858
|
1,985,821
|
23,719,166
|
Proposal No. 2: Ratification
of Independent Registered Public Accounting Firm. The stockholders ratified BDO USA, LLP as the Company’s independent
registered public accounting firm as follows:
Votes For
|
44,802,473
|
Votes Against
|
268,520
|
Abstentions
|
152,852
|
SIGNATURES
Pursuant to the requirements of the
Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
ANAVEX LIFE SCIENCES CORP.
|
|
|
|
|
|
/s/ Christopher Missling
|
|
Name: Christopher Missling, PhD
|
|
Title: Chief Executive Officer
|
|
|
Date: April 8, 2020
|
|
Anavex Life Sciences (NASDAQ:AVXL)
Historical Stock Chart
From Aug 2024 to Sep 2024
Anavex Life Sciences (NASDAQ:AVXL)
Historical Stock Chart
From Sep 2023 to Sep 2024